To Get Full Access :

Izervay

Izervay is a monthly injection into the eye to treat geographic atrophy caused by age-related macular degeneration. It slows vision loss by targeting a key protein involved in retinal cell death.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Avacincaptad Pegol
  • Innovator :

    IVERIC BIO INC
  • Approval Date :

    04-Aug-23
  • NCE-1 Date :

    04-Aug-27
  • NCE Date :

    04-Aug-28
  • Dosage Form :

    Intravitreal Solution
  • Strength :

    EQ 2MG BASE/0.1ML
  • Therapeutic Category :

    Ophthalmic
  • Revenue ($M) :

    382

Year-wise Projected Sales ($M) :

  • 2025 :

    584
  • 2026 :

    812
  • 2027 :

    1,026
  • 2028 :

    1,209
  • 2029 :

    1,418
  • 2030 :

    1,599
  • 2031 :

    1,775
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?